|Bid||84.82 x 900|
|Ask||84.96 x 800|
|Day's range||82.42 - 85.94|
|52-week range||30.05 - 189.89|
|Beta (5Y monthly)||1.49|
|PE ratio (TTM)||4.84|
|Earnings date||08 Nov 2021 - 12 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||141.00|
Moderna's (NASDAQ: MRNA) COVID-19 vaccine has created a multibillion-dollar revenue stream for the company, but is the massive $130 billion valuation of the business justified? In this Fool Live video clip, recorded on Oct. 4, Fool.com contributors Rachel Warren and Jason Hall discuss whether Moderna could be a smart buy despite its nosebleed-level valuation. Rachel Warren: It's funny, because I write about healthcare stocks a lot and I'm a healthcare writer here at the Fool.
After all, Wall Street doesn't sell a stock unless it believes there is a better place for the money -- at least in the short term. Knowing you plan to hold for years, and not having anyone but yourself to answer to, can focus your analysis on the company and its prospects. As company reputations go, Johnson & Johnson offers one of the strangest juxtapositions.
The company is leveraging success with its COVID-19 tests to position itself better for a post-pandemic world.